4D Molecular Therapeutics (NASDAQ:FDMT) Given “Outperform” Rating at Royal Bank Of Canada

Royal Bank Of Canada reissued their outperform rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report issued on Tuesday, Marketbeat.com reports. Royal Bank Of Canada currently has a $26.00 target price on the stock.

Several other research analysts have also issued reports on the stock. Roth Capital decreased their price target on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $29.50.

4D Molecular Therapeutics Trading Down 0.3%

Shares of 4D Molecular Therapeutics stock opened at $11.24 on Tuesday. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $11.65. The stock has a market cap of $524.91 million, a PE ratio of -3.18 and a beta of 2.93. The company’s 50-day moving average price is $7.78 and its two-hundred day moving average price is $5.26.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%.The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.52 million. On average, equities analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC boosted its position in shares of 4D Molecular Therapeutics by 1,103.4% in the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock worth $1,290,000 after buying an additional 367,317 shares during the period. Invesco Ltd. lifted its stake in 4D Molecular Therapeutics by 318.3% in the 1st quarter. Invesco Ltd. now owns 117,768 shares of the company’s stock worth $380,000 after acquiring an additional 89,611 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in 4D Molecular Therapeutics in the 1st quarter worth about $63,000. Federated Hermes Inc. boosted its position in 4D Molecular Therapeutics by 33,131.8% during the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock worth $4,038,000 after acquiring an additional 1,246,419 shares during the period. Finally, Nuveen LLC purchased a new position in 4D Molecular Therapeutics during the 1st quarter valued at about $486,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.